Title: Liver SABR- an effective and feasible alternative to surgery during the COVID19 pandemic

Article Type: Correspondence

Keywords: SABR; Liver directed therapy; Covid-19

Corresponding Author: Dr. Katharine Aitken, MBBS MSc BSc FRCR

Corresponding Author's Institution: Royal Marsden Hospital

First Author: Katharine Aitken, MBBS MSc BSc FRCR

Order of Authors: Katharine Aitken, MBBS MSc BSc FRCR; James Good, FRCR; Maria Hawkins, FRCR; Derek Grose, FRCR; Somnath Mukherjee, FRCR; Mark Harrison, FRCR; Ganesh Radhakrishna, FRCR

Manuscript Region of Origin: UNITED KINGDOM
Liver SABR: an effective and feasible alternative to surgery during the COVID19 pandemic

Authors:
Katharine Aitken MRCP FRCR MD*1, James Good MRCP FRCR PhD2, Maria Hawkins MRCP FRCR MD3, Derek Grose MRCP FRCR MD4, Somnath Mukherjee MRCP FRCR MD5, Mark Harrison FRCP FRCR PhD6, Ganesh Radhakrishna MRCP FRCR7

*Corresponding author

Affiliations:
1. The Royal Marsden NHS Foundation Trust, London, UK
2. University Hospitals Birmingham NHS Foundation Trust, UK
3. Department of Medical Physics and Biomedical Engineering, University College London, UK
4. Beatson West of Scotland Cancer Centre, Glasgow, UK
5. CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, UK
6. Mount Vernon Cancer Centre, UK
7. The Christie NHS Foundation Trust, Manchester, UK
Dear Madam

The COVID-19 epidemic is having an unprecedented impact on UK cancer services. Access to radical surgery has been severely restricted and resources for systemic therapy provision are being limited as the crisis unfolds. Radiotherapy resources are rightly being focused on patients being treated with curative intent. However, it is our experience that access to stereotactic ablative radiotherapy (SABR) is diminishing, predominantly due to staffing shortages.

SABR offers a non-invasive, outpatient ablative approach with minimal hospital footfall and with lower immunosuppressive risks than chemotherapy. The recently published long term outcomes of the SABR COMET study illustrate the ability of SABR to substantially impact survival across tumour types (1). The NHS England Commissioning through Evaluation process has shown that SABR can be safely delivered in the UK (2, 3).

SABR requires specialist multi-disciplinary expertise. The majority of radiotherapy departments are planning to maintain their capacity for category 1-4 treatments (4) and many have therefore suspended SABR for oligometastatic disease. However, we are concerned that diminishing access to SABR, at a time when access to other curative local treatment modalities is already restricted, will result in poorer patient outcomes in the short and medium term when this need not be the case.

Patients with liver-limited colorectal cancer have a five year survival of 40% following surgery (5). Given the evidence supporting SABR for colorectal liver metastases (6), we believe this should be prioritised if patients are unable to access surgery and interventional ablative techniques. Similarly, SABR should be considered for patients with hepatocellular carcinoma while access to other services (particularly transplant) is limited. We urge radiotherapy departments to preserve access to SABR for patients in these situations, particularly as the COVID-19 epidemic wanes and staffing levels allow re-establishment of normal services.

Yours faithfully

References


<table>
<thead>
<tr>
<th></th>
<th>Author Contributions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>guarantor of integrity of the entire study - All</td>
</tr>
<tr>
<td>2</td>
<td>study concepts and design - K Aitken, G Radhakrishna</td>
</tr>
<tr>
<td>3</td>
<td>literature research - K Aitken</td>
</tr>
<tr>
<td>4</td>
<td>clinical studies - N/A</td>
</tr>
<tr>
<td>5</td>
<td>experimental studies / data analysis - N/A</td>
</tr>
<tr>
<td>6</td>
<td>statistical analysis - N/A</td>
</tr>
<tr>
<td>7</td>
<td>manuscript preparation - K Aitken</td>
</tr>
<tr>
<td>8</td>
<td>manuscript editing - K Aiken</td>
</tr>
</tbody>
</table>